Recent Updates
Recently added Catalysts

Nutriband Inc.

NTRBFDA catalysts, PDUFA dates & pipeline intelligence
$5.59
▼ -0.23 · -3.87%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full NTRB financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.8052W HIGH $9.19
Volume
18.87 K
Value Traded
106.80 K
Short % Float
2.64%
Days to Cover
4.9
-3.99%Week
-7.83%1 Month
+60.29%3 Month
+60.29%6 Month
-76.41%5 Year
-48.21%All Time

Cash Data

Unlock NTRB cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
67.89 M
EPS (TTM)
-0.57
P/E Ratio
-
Ent. Value
65.32 M
Total Shares
12.16 M
Float Shares
5.25 M
Insiders
56.82%
Institutions
3.41%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every NTRB catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

NTRB Catalyst Timeline

Dated clinical, regulatory and corporate events for Nutriband Inc.

Unlock the full NTRB catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How NTRB actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all NTRB historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Nutriband Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every NTRB program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every NTRB trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock NTRB insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Goodman GeraldOfficer (Chief Financial Officer)Option 87,500 179,500 held$1.93 06/06/2024
Unlock the full NTRB insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in NTRB for Q3 2026.
Unlock every fund holding NTRB
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in NTRB
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see NTRB ownership
Insider and institutional ownership, quarter by quarter.

NTRB Short Interest

Shares sold short, counted twice a month.

2.64%
Short % of Float
of tradable shares sold short
138.8K
Shares Sold Short
-12.0% vs prior count
4.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
28.3K
Avg Daily Volume
the average used for days to cover
Unlock NTRB short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock NTRB option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live NTRB option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock NTRB options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How NTRB ranks across every disease it competes in

Competitive Position is a premium feature
See how NTRB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

NTRB News

NTRB
Nov 17, 2026
NTRBFDA Updates
▼ -3.9%today

Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System

Nutriband Inc. announced it received a Notice of Allowance from the USPTO for trademarks related to its abuse-deterrent fentanyl transdermal system. The company plans to secure full trademark registration and is preparing to submit its brand name to regulatory bodies. The product could achieve significant annual sales, addressing a global need for effective pain management.

Read more →
NTRB
Oct 13, 2026
NTRBGeneral
▲ +11.5%on this news

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274

Nutriband Inc. reported the exercise of 272,671 NTRBW warrants at $6.43, generating $1,753,274. The funds will be allocated to the clinical development of AVERSA Fentanyl and its NDA submission to the FDA. AVERSA Fentanyl aims to be the first opioid patch with abuse deterrent properties, potentially reaching annual sales of $80 million to $200 million.

Read more →
NTRB
Oct 8, 2026
NTRBGeneral
▼ -10.4%on this newsshared move

Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology

Nutriband Inc. has filed a non-provisional patent application with the USPTO to enhance the intellectual property protection of its AVERSA™ transdermal abuse deterrent technology. This application covers improved formulations and methods that could extend patent protection for AVERSA™ products to 2046. The technology aims to prevent the abuse of drugs like opioids while ensuring patient access.

Read more →
NTRB
Oct 1, 2026
NTRBGeneral

Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders

Nutriband CEO Gareth Sheridan marked the company's fifth anniversary on Nasdaq, reflecting on milestones since the October 1, 2021 uplisting. AVERSA™ Fentanyl advanced toward an IND filing while 2021 warrants expired as scheduled. The company reported record revenues and secured patents in 46 countries. Nutriband now aims to file an NDA for its abuse-deterrent fentanyl patch.

Read more →
NTRB
Sep 29, 2026
NTRBGeneral

Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis

Nutriband CEO Gareth Sheridan appeared in a new documentary by filmmaker Nick Shirley addressing the U.S. opioid crisis. He discussed how the company's AVERSA™ abuse-deterrent platform aims to reduce medication misuse while preserving patient access. The film highlights the complex challenges surrounding prescription drug abuse and diversion.

Read more →
NTRB
Sep 25, 2026
NTRBGeneral
▼ -11%on this newsshared move

Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board

Nutriband Inc. appointed Robert J. O'Neill, a decorated Navy SEAL, to its Advisory Board. O'Neill, known for his leadership and advocacy for veteran health, will support Nutriband's strategy as it advances its AVERSA Fentanyl patch. His extensive military experience and commitment to health treatments are seen as valuable assets for the company.

Read more →
NTRB
Sep 22, 2026
NTRBGeneral
▼ -13%on this newsshared move

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Nutriband Inc. announced that its outstanding warrants will expire on September 30, 2026, at 5 PM ET. The company will not extend the expiration date or reprice the warrants. Currently, there are 910,904 warrants outstanding, which could yield $5,856,112 if fully exercised at the strike price of $6.43.

Read more →
NTRB
Sep 9, 2026
NTRBConferences/Events

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

Nutriband Inc. announced that CEO Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The event will facilitate networking among biotechnology executives and investors. The company is focused on developing its AVERSA™ abuse-deterrent transdermal technology, which aims to enhance the safety of drugs like fentanyl.

Read more →
NTRB
Sep 8, 2026
NTRBFDA Updates

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Nutriband announced it received a Notice of Publication from the USPTO for trademarks related to its abuse deterrent fentanyl patch. The company plans to submit the brand name to the FDA for approval. The product, utilizing AVERSA technology, aims to prevent misuse and has significant sales potential in the US and global markets.

Read more →
NTRB
Aug 13, 2026
NTRBConferences/Events

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Nutriband Inc. announced that CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on August 26. The event takes place August 25-26 at the Sandy Springs Performing Arts Centre in Georgia. Sheridan’s appearance is part of the CEO spotlight segment. The company develops transdermal pharmaceutical products using its AVERSA technology.

Read more →
NTRB
May 15, 2026
NTRBConferences/Events

Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference

Nutriband Inc. will present its expanding AI wellness product line at the ECRM conference in June 2026. The company aims to engage with major retailers, including Walmart and Walgreens, to discuss new product placements. Notable product launches include AI Performance Tape, AI Energy Patches, and AI Sleep solutions, which cater to the growing wellness market.

Read more →
NTRB
Apr 22, 2026
NTRBGeneral

Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

Nutriband Inc. CEO Gareth Sheridan appeared on the Jack Neel Podcast to discuss the ongoing US fentanyl crisis and provide insights into the company's innovative AVERSA abuse-deterrent technology. This technology aims to enhance safety for patients who require potent medications while minimizing risks of abuse and misuse. The company continues to develop products utilizing this technology, presenting an opportunity for Nutriband to play a significant role in addressing opioid-related challenges. Sheridan's participation in the podcast underscores Nutriband's proactive approach to tackling drug abuse issues.

Read more →
NTRB
Mar 30, 2026
NTRBFDA Updates
▼ -10.4%on this news

SELECTS COMMERCIAL BRAND NAME FOR ITS ABUSE DETERRENT FENTANYL PATCH

Nutriband Inc. has announced the selection of a worldwide brand name for its leading product, an abuse deterrent fentanyl transdermal system, which will be submitted to the FDA for approval. This product's innovative AVERSA technology aims to reduce the risks associated with misuse of fentanyl, addressing a significant medical need. With potential peak annual sales between $80 million and $200 million, Nutriband's initiative highlights the importance of effective branding and regulatory compliance in pharmaceutical development. The company is strategically partnering with Brand Institute to enhance its market presence and intellectual property rights.

Read more →
NTRB
Mar 18, 2026
NTRBFDA Updates

Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica

Nutriband Inc. has announced that its line of Kinesiology Tapes has been approved for import and sale in Costa Rica by the Ministry of Health. The company will work with its exclusive distribution partner, Innomedica CCB, to begin marketing these products. This approval signifies a positive step for Nutriband as it seeks to expand its product offerings in the region, including its mosquito repellent patch line. The company is also focused on developing its AVERSA™ abuse-deterrent technology for transdermal products.

Read more →
NTRB
Feb 17, 2026
NTRBGeneral

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

Nutriband Inc. has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for its AVERSA Fentanyl product, pending regulatory approval. Innomedica will also oversee and finance the necessary regulatory approvals for AVERSA and all sports tape products from Nutriband's subsidiary. The AVERSA technology aims to deter drug abuse and misuse through its innovative transdermal patches. This partnership marks a significant step for Nutriband in advancing its product offerings in the market.

Read more →
NTRB
Jan 30, 2026
NTRBGeneral
▲ +6%on this news

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

Nutriband Inc. reported collecting $30,000 in weekly penalties from EarthVision Bio for delays in closing the Pocono Pharma sale. The company also announced the addition of two new directors to its board. Additionally, Nutriband reminded shareholders that 910,904 warrants will expire on October 1, 2026.

Read more →
NTRB
Dec 31, 2025
NTRBGeneral

Nutriband CEO Publishes Letter to Shareholders

Nutriband Inc. announced it agreed to sell 90% of its Pocono subsidiary to EarthVision Bio for $5 million. The transaction adds $5 million to the company’s bottom line without diluting shareholders. CEO Gareth Sheridan also highlighted a 25% preferred stock dividend issued in July. The firm expects warrant expiration in October 2026 to reduce stock volatility.

Read more →
NTRB
Dec 31, 2025
NTRBGeneral

Nutriband Inc. Signs Agreement to Sell Majority

Nutriband Inc. has signed an agreement to sell a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million. Following the sale, Nutriband shareholders will retain a 10% stake in EarthVision Bio, which focuses on sustainable product development. The proceeds from this transaction will be utilized for further development of AVERSA Fentanyl, an innovative abuse-deterrent opioid patch. This transaction is set to close by December 31, 2025, reflecting a strategic move to bolster Nutriband's pharmaceutical portfolio.

Read more →
NTRB
Dec 29, 2025
NTRBGeneral
▲ +16%on this newsshared move

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million. Following the transaction, Nutriband will retain a 10% stake in EarthVision Bio, which is focused on sustainable product development. The funds from this sale will be utilized to advance Nutriband's AVERSA Fentanyl project, an innovative abuse-deterrent opioid patch.

Read more →
NTRB
Dec 18, 2025
NTRBFDA Updates

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Nutriband Inc. has responded to the U.S. Executive Order designating illicit fentanyl as a weapon of mass destruction by emphasizing the importance of maintaining access to FDA-approved prescription fentanyl therapies for pain management. The company is developing Aversa™ Fentanyl, an abuse-deterrent transdermal patch designed to deter misuse while ensuring that patients receive necessary treatment for severe chronic pain. With the potential for significant market sales and a robust intellectual property portfolio, Nutriband aims to provide safer alternatives to existing fentanyl products.

Read more →

About Nutriband Inc.

Orlando, FL 3 employees nutriband.com
Headquarters121 S. ORANGE AVE., ORLANDO, FL, 32801
BIOPHARMAWATCH ELITE
Trade the next NTRB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime